A new enzyme replacement therapy for Pompe disease has been approved by the US Food and Drug Administration, which has been shown to help reduce glycogen accumulation in muscles – a feature of the disease. The therapy, Nexviazyme (avalglucosidase), is a version of Myozyme (alglucosidase alfa), which was approved by the FDA in 2006. Both therapies were developed by Genzyme, which is part of Sanofi SA.
